8-K: Nuo Therapeutics Reports Q1 2026 Results, Aurix Growth

Nuo Therapeutics announced strong first quarter 2026 financial results, with total revenues soaring 169% year-over-year, driven by significant growth in its Aurix product line.

Summary

• Nuo Therapeutics reported first quarter 2026 revenues of approximately $1.3 million, a 169% increase compared to the first quarter of 2025 and a 20% increase from the fourth quarter of 2025.
• Aurix branded product revenues saw a sequential increase of over 30% compared to the fourth quarter of 2025.
• The company reported a net operating loss of approximately $446,000 for Q1 2026, an improvement from the $745,000 net operating loss in Q1 2025.
• Nuo Therapeutics entered into a Loan and Security Agreement, securing initial funding of $1.0 million to support working capital and growth initiatives.
• The company noted robust demand for its Aurix product in private physician office settings, benefiting from improved Medicare reimbursement for skin substitutes and a changed overall reimbursement landscape.
• Management expressed confidence in Aurix's market position and future growth potential, despite navigating market uncertainty due to recent disruptions in the wound care market.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing due to significant revenue growth, improved operating loss, and new funding, despite ongoing market uncertainties.

Positives

• Total revenues increased by 169% year-over-year to approximately $1.3 million in Q1 2026.
• Product revenues reached approximately $1,224,000 in Q1 2026.
• Aurix branded product revenues grew over 30% sequentially from Q4 2025.
• Net operating loss improved to approximately $446,000 in Q1 2026, down from $745,000 in Q1 2025.
• Secured $1.0 million in initial funding through a Loan and Security Agreement to support growth.
• Witnessing robust demand for Aurix in private physician offices.
• Favorable market response due to improved Medicare reimbursement for Aurix and overall reimbursement landscape changes.

Negatives

• The company reported a net loss of $618,466 for Q1 2026.
• Stockholders' deficit increased to $1,383,863 as of March 31, 2026, from $956,559 as of December 31, 2025.
• Total liabilities increased to $3,329,532 as of March 31, 2026, from $2,802,221 as of December 31, 2025.
• Cash decreased to $263,827 as of March 31, 2026, from $548,946 as of December 31, 2025.

Risks

• The disruption within the wound care market, while creating opportunities, also presents challenges and overall market uncertainty for Nuo.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially.
• Potential risks and uncertainties are discussed in Nuo's public filings with the U.S. Securities and Exchange Commission.

Future Outlook

Nuo Therapeutics is enthusiastic about the remainder of 2026 and anticipates sharing future developments and results. The company believes it is attractively positioned for strong and attractive long-term growth, moving closer to breakeven operations with the support of new funding.

Management Comments

• "It would be an understatement to describe the past 12 months and most particularly the first several months of 2026 in the advanced wound care market as anything other than dramatic."
• "Fortunately, we have in Aurix, and Smith+Nephew has in its private label branded offering, a product which we believe is right for the time and the space."
• "With the January 1st change in reimbursement for skin substitutes, interest in autologous platelet rich plasma (PRP) was immediate and vigorous."
• "The disruption within the wound care market is substantial and has created significant uncertainty for many stakeholders including, of course, the provider community."
• "While we have substantial confidence in the benefits available to patients seeking treatment options for non-healing chronic wounds and the wider system from effective PRP products, the disruption does not come without challenges to Nuo as we also navigate the overall market uncertainty."
• "However, we believe we are very attractively positioned for long term success with potential for strong and attractive growth well into the future."
• "With this financial results release, we are making the commitment to now regularly report on our progress beyond our periodic filings with the US Securities and Exchange Commission."
• "We are enthusiastic about the remainder of 2026 and look forward to sharing future developments and our related results."

Industry Context

StockSavvy.ai notes that Nuo Therapeutics is operating in the dynamic regenerative therapies market for chronic wound care. The recent changes in Medicare reimbursement for skin substitutes, as highlighted by the company, are a significant industry trend impacting demand for products like Aurix and creating both opportunities and uncertainties for market participants.

Related Party Transactions

• Note payable - related party of $205,000 as of March 31, 2026.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong revenue growth and improved financial performance, offset by ongoing market uncertainties and a net loss.
• Creditors: The new loan agreement provides working capital, potentially improving the company's ability to meet its obligations.
• Providers (Physician Offices): Benefit from robust demand for Aurix and improved reimbursement landscape, potentially leading to better patient outcomes.
• Suppliers: Increased product sales may lead to higher demand for raw materials and services.

Next Steps

• Regularly report on progress beyond periodic SEC filings.
• Continue to invest in growth and move closer to breakeven operations.
• Share future developments and related results.

Key Dates

Recommendation

The significant revenue growth and operational improvements are positive indicators. However, the company still operates at a net loss, faces market uncertainties, and the long-term impact of reimbursement changes remains to be fully seen. The new funding provides a runway, but continued execution and path to profitability are key. A 'hold' recommendation reflects cautious optimism pending further evidence of sustained growth and profitability.

Keywords

Nuo Therapeutics, Aurix, Chronic Wound Care, Regenerative Therapies, Medical Device, Financial Results, Q1 2026, Reimbursement